Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | STAT1 | P42224 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496545 | 0.81 | PTGS1 (0.65) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19642547 | 0.77 | ALDH1A1 (0.58) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL23402744 | 0.74 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL6451935 | 0.74 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19642663 | 0.73 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19625345 | 0.73 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL1143708 | 0.73 | RAB9A (1.00) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19660147 | 0.72 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19660194 | 0.72 | AHR (0.49) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 | |
| SCHEMBL19626646 | 0.71 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTRAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-31 | — | — | US | claimed |
| EP-3212190-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | Université De Reims Champagne-Ardenne (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-31 | — | — | US | disclosed |
| WO-2016066973-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | PEX3, NCOA3, NCAPD3 | SMN1; SMN2 1466/4885MAPT 4332/4885RAB9A 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.